Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer

British Journal of Cancer

Volumn 107, Issue 10, 2012, Pages 1684-1691

  Myklebust, M P ^a   Li, Z ^b   Tran, T H ^b   Rui, H ^b   Knudsen, E S ^b   Elsaleh, H ^c   Fluge, O ^d   Vonen, B ^e   Myrvold, H E ^f   Leh, S ^d   Tveit, K M ^g   Pestell, R G ^b   Dahl, O ^a,d  

^a UNIVERSITY OF BERGEN   (Norway)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c The Australian National University   (Australia)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Colorectal cancer; Cyclin D1a; Cyclin D1b; IHC; Treatment response

Indexed keywords

CYCLIN D1; CYCLIN D1A; CYCLIN D1B; FLUOROURACIL; ISOPROTEIN; LEVAMISOLE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYCLIN D1; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LEVAMISOLE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84869089879     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.463     Document Type: Article

References (52)

1. Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantaggiati M, Somasundaram K, Thimmapaya B, Pestell RG (1999) Activation of the cyclin D1 gene by the E1A-Associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 274(48): 34186-34195. (Pubitemid 129511756)
2. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR, Weinstein IB (1997) Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57(8): 1569-1574. (Pubitemid 27175576)
3. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB, Holt PR (1996) Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110(3): 669-674. (Pubitemid 26071834)
4. Bala S, Peltomaki P (2001) CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 61(16): 6042-6045. (Pubitemid 32762536)
5. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, Quirke P (2002) DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study. Lancet 360(9343): 1381-1391. (Pubitemid 35341303)
6. Besson A, Dowdy SF, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14(2): 159-169. (Pubitemid 351189186)
7. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11(5): 1005-1011.
8. Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC (2003) A case-control study of cyclin D1 CCND1 870A-G polymorphism and bladder cancer. Carcinogenesis 24(10): 1645-1650. (Pubitemid 37304669)
9. Dahl O, Fluge O, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM (2009) Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 48(3): 368-376.
10. Derwinger K, Carlsson G, Gustavsson B (2007) Stage migration in colorectal cancer related to improved lymph node assessment. Eur J Surg Oncol 33(7): 849-853. (Pubitemid 47279054)
11. Diehl JA (2002) Cycling to cancer with cyclin D1. Cancer Biol Ther 1(3): 226-231.
12. Dolled-Filhart M, Ryden L, Cregger M, Jirstrom K, Harigopal M, Camp RL, Rimm DL (2006) Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 12(21): 6459-6468. (Pubitemid 44799719)
13. Edler D, Ohrling K, Hallstrom M, Karlberg M, Ragnhammar P (2007) The number of analyzed lymph nodes Y a prognostic factor in colorectal cancer. Acta Oncol 46(7): 975-981. (Pubitemid 47537177)
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet].
15. Fluge O, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, Lilleng R, Eide TJ, Halvorsen TB, Tveit KM, Otte AP, Akslen LA, Dahl O (2009) Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 101(8): 1282-1289.
16. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145(12): 5439-5447. (Pubitemid 39564581)
17. Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R, Sukhatme VP (2002) Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 277(19): 16464-16469. (Pubitemid 34967659)
18. Hayes DF, Trock B, Harris AL (1998) Assessing the clinical impact of prognostic factors: when is 'statistically significant' clinically useful? Breast Cancer Res Treat 52(1-3): 305-319.
19. Holley SL, Parkes G, Matthias C, Bockmuhl U, Jahnke V, Leder K, Strange RC, Fryer AA, Hoban PR (2001) Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol 159(5): 1917-1924. (Pubitemid 33062533)
20. Howe D, Lynas C (2001) The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 86(6): 563-569. (Pubitemid 32601099)
21. Hulit J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, Shah S, Byers SW, Mahmood R, Augenlicht LH, Russell R, Pestell RG (2004) Cyclin D1. genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 24(17): 7598-7611. (Pubitemid 39121486)
22. Inaba T, Matsushime H, Valentine M, Roussel MF, Sherr CJ, Look AT (1992) Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics 13(3): 565-574.
23. Ioachim E (2008) Expression patterns of cyclins D1, E and cyclindependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Int J Clin Pract 62(11): 1736-1743.
24. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, Kunkel TA, van Harn T, Xia B, Correll M, Quackenbush J, Livingston DM, Gygi SP, Sicinski P (2011) A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474(7350): 230-234.
25. Kong S, Wei Q, Amos CI, Lynch PM, Levin B, Zong J, Frazier ML (2001) Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 93(14): 1106-1108. (Pubitemid 32717544)
26. Kouraklis G, Theocharis S, Vamvakas P, Vagianos C, Glinavou A, Giaginis C, Sioka C (2006) Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer. World J Surg Oncol 4: 5.
27. Le Marchand L, Seifried A, Lum-Jones A, Donlon T, Wilkens LR (2003) Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 290(21): 2843-2848. (Pubitemid 37509493)
28. Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, Wang M, Soutoglou E, Knudsen ES, Pestell RG (2010) Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 70(21): 8802-8811.
29. Lu F, Gladden AB, Diehl JA (2003) An alternatively spliced cyclin D1. isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63(21): 7056-7061. (Pubitemid 37413439)
30. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375(6531): 503-506.
31. Maeda K, Chung YS, Kang SM, Ogawa M, Onoda N, Nakata B, Nishiguchi Y, Ikehara T, Okuno M, Sowa M (1997) Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74(3): 310-315. (Pubitemid 27321801)
32. McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FY, Loane JF, Murray GI, McLeod HL (2000a) Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res 6(3): 1113-1118. (Pubitemid 30159374)
33. McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, Cassidy J, McLeod HL, Murray GI (2002) Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 196(4): 386-393. (Pubitemid 34262849)
34. McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J, McLeod HL (2000b) Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer 88(1): 77-81.
35. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, Rui H, Pestell RG, Lisanti MP (2009) Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol 174(4): 1172-1190.
36. Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, Fich A, Gheber L (2005) Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer 93(3): 338-345. (Pubitemid 43080036)
37. Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM, Stanley MW, Albrecht JH (2005) Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 280(1): 768-776. (Pubitemid 40165045)
38. Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA, Fuchs CS (2009) A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 15(13): 4431-4438.
39. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15(5): 2612-2624.
40. Pontano LL, Aggarwal P, Barbash O, Brown EJ, Bassing CH, Diehl JA (2008) Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. Mol Cell Biol 28(23): 7245-7258.
41. Schernhammer ES, Tranah GJ, Giovannucci E, Chan AT, Ma J, Colditz GA, Hunter DJ, Willett WC, Fuchs CS (2006) Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma. Br J Cancer 94(6): 928-934.
42. Sherr CJ (1995) D-type cyclins. Trends Biochem Sci 20(5): 187-190.
43. Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclindependent kinases. Genes Dev 18(22): 2699-2711. (Pubitemid 39507762)
44. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES (2003) Cyclin D1 splice variants. differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278(32): 30339-30347. (Pubitemid 36962428)
45. Vidal A, Koff A (2000) Cell-cycle inhibitors: three families united by a common cause. Gene 247(1-2): 1-15. (Pubitemid 30201556)
46. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG (2005) Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res 65(15): 6557-6567. (Pubitemid 41060691)
47. Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, Fu M, Leader JE, Quong A, Novikoff PM, Pestell RG (2006) Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci USA 103(31): 11567-11572. (Pubitemid 44182492)
48. Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, Tsuchiya N, Sato K, Ohyama C, Nakamura A, Ogawa O, Kato T (2003) Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 103(1): 116-120. (Pubitemid 35424214)
49. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O, Kato T (2002) Cyclin D1. gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23(2): 257-264. (Pubitemid 34224000)
50. Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES (2008) Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 68(14): 5628-5638.
51. Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J, Jirstrom K (2011) Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. Biol Sex Differ 2: 10.
52. Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemasa I, Ikeda M, Fujio Y, Sekimoto M, Matsuura N, Weinstein IB, Monden M (2006) Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumour vascularization. Clin Cancer Res 12(15): 4720-4729(Pubitemid 44297826)